New indications for antidepressants
by
Schatzberg AF
Department of Psychiatry and Behavioral Sciences,
Stanford University School of Medicine,
Calif 94305-5548, USA.
J Clin Psychiatry 2000 ;61 Suppl 11:9-17


ABSTRACT

The second and third generation of antidepressants, i.e., the selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine, are proving to be useful in a variety of seemingly diverse disorders, including most anxiety disorders. In addition to receiving approval from the U.S. Food and Drug Administration (FDA) for major depressive disorder, some of the newer antidepressants have received FDA approval for other disorders, e.g., generalized anxiety disorder (venlafaxine), bulimia nervosa (fluoxetine), obsessive-compulsive disorder (fluvoxamine, paroxetine, sertraline, and fluoxetine), social phobia (paroxetine), panic disorder (sertraline, paroxetine), and posttraumatic stress disorder (sertraline). In controlled studies, these agents have also shown usefulness in premenstrual dysphoric disorder, borderline personality disorder, obesity, smoking cessation, and alcoholism. This article describes the new and potential indications for recently developed antidepressants and the studies that suggested these indications.

GAD
OCD
PTSD
SSRIs
Prozac
Options
Sertraline
Paroxetine
Venlafaxine
Fluvoxamine
SSRIs/SNRIs
Comparisons
Panic disorder
Major depression
Super small doses
New antidepressants
Sub-types of depression
SNaRIs, NaSSAs, and NaRIs
Antidepressants and the elderly


Refs
and further reading

HOME
HedWeb
Nootropics
Cocaine.org
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family